Chemotherapy News and Research

Latest Chemotherapy News and Research

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today summarized new data highlighting the progress of OncoMed's pipeline of anti-cancer biologics presented this week in an oral presentation and five posters at the Annual Meeting of the American Association of Cancer Research in Washington, DC.

11 Apr 2013

QOPI Certification Program certifies MD Anderson Cancer Center Orlando

MD Anderson Cancer Center Orlando, known for inspiring hope through extraordinary care in Central Florida has now received a prestigious national certification from the Quality Oncology Practice Initiative (QOPI) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO). The QOPI Certification Program (QCP) certifies oncology practices that meet the highest quality standards for cancer care.

11 Apr 2013

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

Researchers may have discovered a more accurate way to predict how long patients with the deadliest form of brain cancer will live, according to an analysis by researchers from the University of Alabama at Birmingham published today in the journal PLOS ONE.

11 Apr 2013

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

Spirogen, a leading oncology-focused company developing DNA sequence targeted agents, and BioAtla LLC, a San Diego headquartered antibody therapeutics developer, today announced new data on the use of pyrrolobenzodiazepine (PBD) dimers as warheads in antibody drug conjugates (ADCs) at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC.

11 Apr 2013

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals, Inc. today announced additional positive interim data from an ongoing Phase I/II clinical trial of VAL-083 in patients with recurrent glioblastoma multiforme (GBM) or progressive secondary brain tumor.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors, according findings to be presented by Fox Chase Cancer Center researchers at the AACR Annual Meeting 2013 on Tuesday, April 9.

10 Apr 2013

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

Human osteosarcoma samples are hard to come by, making the disease difficult to study. However, K9 bone cancer is genetically indistinguishable from the human form of the disease, and over 10,000 canine patients develop the disease every year.

10 Apr 2013

New study shows combination therapy is effective in treating sarcoma tumors

Researchers at Moffitt Cancer Center and colleagues at the University of South Florida have found that when given together, a two-drug combination acts synergistically in test animals modeled with sarcoma tumors.

10 Apr 2013

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy.

10 Apr 2013

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.

10 Apr 2013

Viewpoints: Looking for the budget's true bottom line; The debate on Plan B reignited; Medicare cuts have impact

President Obama will release his overdue budget on Wednesday. It will doubtless project a reduction in the federal budget deficit - a projection that journalists, commentators and policy makers should ignore.

10 Apr 2013

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found.

10 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have their metastases surgically removed.

10 Apr 2013

Research sheds light on malaria-related parasite's transition from acute to chronic stage

A new discovery about the malaria-related parasite Toxoplasma gondii -- which can threaten babies, AIDS patients, the elderly and others with weakened immune function -- may help solve the mystery of how this single-celled parasite establishes life-long infections in people.

10 Apr 2013

New immunotherapies are seldom developed for childhood cancer

More often than not, cancer immunotherapies that work in adults are used in modified ways in children. Seldom are new therapies developed just for children, primarily because of the small number of pediatric patients relative to the adult cancer patient population.

9 Apr 2013

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Autophagy, the process by which cells that are starved for food resort to chewing up their own damaged proteins and membranes and recycling them into fuel, has emerged as a key pathway that cancer cells use to survive in the face of assault by chemotherapy and radiation.

9 Apr 2013

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy.

9 Apr 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

QOPI Certification Program certifies MD Anderson Cancer Center Orlando

Study reports role of cytochrome c oxidase as prognostic marker in GBM patients' tumor tissues

New data on use of PBD dimers as warheads in ADCs presented at AACR annual meeting

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

FDA accepts Merck's NDA for NOXAFIL tablets

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

New chemotherapy regimen appears to produce minimal side effects in lung cancer patients

Researchers discover novel protein that governs metastasis and chemoresistance in pediatric bone cancer

New study shows combination therapy is effective in treating sarcoma tumors

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

Onconova reports positive results from rigosertib Phase 1 trial in patients with advanced solid tumors

Viewpoints: Looking for the budget's true bottom line; The debate on Plan B reignited; Medicare cuts have impact

Gene variations can predispose people to chemotherapy-induced peripheral neuropathy

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Combination of cetuximab and chemotherapy improves tumor shrinkage, extends survival

Research sheds light on malaria-related parasite's transition from acute to chronic stage

New immunotherapies are seldom developed for childhood cancer

Researchers develop predictive biomarker to identify cancer patients who may respond to autophagy inhibitors

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in